Sorry, you need to enable JavaScript to visit this website.

Your Story. In Your Own Words.

Patients and caregivers are invited to share post-diagnosis insights and experiences with HR+/HER2- metastatic breast cancer (mBC). By talking about the impact it has on your daily life, you may provide support to others in the mBC community.

It’s also an opportunity to potentially help others learn more about your experience with IBRANCE. And your story, like so many others, can be meaningful to patients and caregivers coping with mBC.

Your story may appear on IBRANCE.com and in other IBRANCE support or outreach materials.

While sharing your story does make you part of the IBRANCE community, it does not register you to become an IBRANCE Ambassador or to participate in the IBRANCE Ambassador Mentor Program.

The personal information you provide makes it possible for us to help share your story and to follow up with you if necessary.

All fields below are required unless marked as optional.

Fieldset 1
Sworn Statement fieldset

Thank you for your interest in sharing your personal experience with IBRANCE for use in promotional activities. As a standard part of the process of considering personal stories for this purpose, please review the following affidavit (sworn statement):

  • I am 18 years of age or older
  • I live in the United States
  • I/my loved one has been diagnosed with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
  • My physician or my loved one’s physician prescribed IBRANCE combination therapy for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
  • I/my loved one is currently taking IBRANCE as prescribed by my/my loved ones’ physician (if applicable)
Your experience with mBC
Tell Us Your mBC Story fieldset

Tell Us Your mBC Story

By submitting your Content and checking this box, you agree to all of these terms and conditions.

You agree that Pfizer reserves the right to use, or not to use, the Content, and that if Pfizer uses the Content it may be viewed, used, and shared by the general public.

You agree to release Pfizer from any and all liability and claims in connection with Pfizer’s use of the Content, including any claims of copyright infringement, trademark infringement, and violation of right of publicity or privacy.

By submitting your Content and checking this box, you agree to all of these terms and conditions.

You agree not to submit Content (including copyright-protected material) owned in whole or in part by a third party. There will be no compensation for your or your loved one’s time or for the Content that you submit.

This Consent and Release does not address, and you acknowledge that Pfizer is not responsible for, the information collection, use, disclosure, or security practices, or other practices, of any third party, including Facebook and Instagram.

By submitting your Content and checking this box, you agree to all of these terms and conditions.

Privacy Statement

Pfizer understands that your health is a personal matter and respects your privacy. Please review our Privacy Policy so that you may understand the information we collect about you, how we use and protect it, and the choices we offer you with respect to your personal information.

 
Pfizer Oncology Together logo

Turn to Pfizer Oncology Together to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.

Acuda a Pfizer Oncology Together para obtener más información sobre los recursos de asistencia financiera y obtener apoyo personalizado de uno de nuestros Campeones de Atención especializados.

Pfizer Oncology Together care champion icon

CALL 1-844-9-IBRANCE (Monday–Friday 8 AM–8 PM ET)

VISIT PfizerOncologyTogether.com

LLAME AL 1-844-9-IBRANCE (De lunes a viernes de 8:00 a 20:00 h, hora del este)

VISITE PfizerOncologyTogether.com

 
Pfizer Oncology Together logo

Turn to Pfizer Oncology Together to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.

Acuda a Pfizer Oncology Together para obtener más información sobre los recursos de asistencia financiera y obtener apoyo personalizado de uno de nuestros Campeones de Atención especializados.

Pfizer Oncology Together care champion icon

CALL 1-844-9-IBRANCE (Monday–Friday 8 AM–8 PM ET)

VISIT PfizerOncologyTogether.com

LLAME AL 1-844-9-IBRANCE
(De lunes a viernes de 8:00 a 20:00 h, hora del este)

VISITE
PfizerOncologyTogether.com

IMPORTANT SAFETY INFORMATION & INDICATIONS INDICACIONES E INFORMACIÓN DE SEGURIDAD IMPORTANTE

IBRANCE may cause serious side effects, including:

Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your healthcare provider should check your white blood cell counts before and during treatment.

If you develop low white blood cell counts during treatment with IBRANCE, your healthcare provider may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.

Lung problems (pneumonitis). IBRANCE may cause severe inflammation of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including:

  • chest pain
  • cough with or without mucus
  • trouble breathing or shortness of breath

Your healthcare provider may interrupt or stop treatment with IBRANCE completely if your symptoms are severe.

What should I tell my healthcare provider before taking IBRANCE?

Before taking IBRANCE, tell your healthcare provider about all of your medical conditions, including if you:

  • have fever, chills, or any other signs or symptoms of infection.
  • have liver or kidney problems.
  • are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby.
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE. Your healthcare provider may ask you to take a pregnancy test before you start treatment with IBRANCE.
    • Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of IBRANCE.
  • are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. Do not breastfeed during treatment with IBRANCE and for 3 weeks after the last dose.

The most common side effects of IBRANCE include:

  • Low red blood cell counts and low platelet counts. Call your healthcare provider right away if you develop any of these symptoms during treatment:
    • dizziness
    • shortness of breath
    • weakness
    • bleeding or bruising more easily
    • nosebleeds
  • infections
  • tiredness
  • nausea
  • sore mouth
  • abnormalities in liver blood tests
  • diarrhea
  • hair thinning or hair loss
  • vomiting
  • rash
  • loss of appetite

IBRANCE may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider about family planning options before starting IBRANCE if this is a concern for you.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of IBRANCE. Call your doctor for medical advice about side effects.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IBRANCE and other medicines may affect each other, causing side effects.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

Do not drink grapefruit juice or eat grapefruit products while taking IBRANCE as they may increase the amount of IBRANCE in your blood.

Tell your healthcare provider if you start a new medicine. Take IBRANCE exactly as your healthcare provider tells you.

If you take too much IBRANCE, call your healthcare provider right away or go to the nearest hospital emergency room.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS

IBRANCE 125 mg capsules and tablets are a prescription medicine used in adults to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with:

IBRANCE is a prescription medicine used in adults to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with:

  • an aromatase inhibitor as the first hormonal based therapy, or
  • fulvestrant in people with disease progression following hormonal therapy.

Please see Full Prescribing Information and Patient Information.

Please see Full Prescribing Information and Patient Information.

IBRANCE puede causar efectos secundarios graves, entre ellos:

Recuentos bajos de glóbulos blancos (neutropenia). Los recuentos bajos de glóbulos blancos son muy frecuentes cuando se toma IBRANCE y pueden causar infecciones graves que pueden provocar la muerte. Su médico debe verificar sus recuentos de glóbulos blancos antes y durante el tratamiento.

Si presenta recuentos bajos de glóbulos blancos durante el tratamiento con IBRANCE, el médico puede interrumpir el tratamiento, disminuir la dosis o indicarle que espere para comenzar el ciclo de tratamiento. Comuníquele de inmediato a su médico si presenta signos y síntomas de recuentos bajos de glóbulos blancos o de infecciones, como fiebre y escalofríos.

Problemas pulmonares (neumonitis). IBRANCE puede provocar una inflamación de los pulmones grave o potencialmente fatal durante el tratamiento y puede conducir a la muerte. Informe a su profesional médico de inmediato si tiene algún síntoma nuevo o si sus síntomas empeoran, que incluyen:

  • dolor de pecho
  • tos con o sin flema
  • dificultad para respirar o falta de aire

Su médico puede interrumpir o detener por completo el tratamiento con IBRANCE si sus síntomas son intensos.

Antes de tomar IBRANCE, informe a su médico todas sus afecciones médicas, incluyendo si:

  • tiene fiebre, escalofríos o cualquier otro signo o síntoma de infección.
  • tiene problemas hepáticos o renales.
  • está embarazada o planea embarazarse; IBRANCE puede hacer daño a su bebé por nacer.
    • Las mujeres con capacidad de quedar embarazadas deben utilizar un método anticonceptivo eficaz durante el tratamiento y, como mínimo, durante 3 semanas después de tomar la última dosis de IBRANCE. Es posible que su médico le pida someterse a una prueba de embarazo antes de iniciar el tratamiento con IBRANCE.
    • Los hombres que tengan parejas del sexo femenino que puedan quedar embarazadas deben utilizar un método anticonceptivo eficaz durante el tratamiento con IBRANCE y, como mínimo, durante 3 meses después de tomar la última dosis de IBRANCE.
  • está amamantando o planea hacerlo. Se desconoce si IBRANCE se excreta en la leche materna. No amamante mientras esté en tratamiento con IBRANCE ni durante 3 semanas después de tomar la última dosis.

Los efectos secundarios más frecuentes de IBRANCE incluyen:

  • Bajos recuentos de glóbulos rojos y bajos recuentos de plaquetas. Llame de inmediato a su médico si presenta cualquiera de estos síntomas durante el tratamiento:
    • mareos
    • falta de aliento
    • debilidad
    • sangrado o formación de moretones con más facilidad
    • sangrado nasal
  • infecciones
  • cansancio
  • náuseas
  • llagas en la boca
  • anomalías en las pruebas de función hepática
  • diarrea
  • afinamiento o caída del cabello
  • vómitos
  • sarpullido
  • pérdida del apetito

IBRANCE puede causar problemas de fertilidad en los hombres. Esto puede afectar su capacidad de engendrar un hijo. Si esto le preocupa, antes de tomar IBRANCE hable con su proveedor de atención médica sobre sus opciones de planificación familiar.

Estos no son todos los posibles efectos secundarios de IBRANCE. Para obtener más información, consulte a su médico.

Informe a su médico sobre todos los medicamentos que toma, incluidos los medicamentos de venta con receta y los de venta libre, vitaminas y suplementos a base de hierbas. IBRANCE y otros medicamentos pueden afectarse mutuamente, causando efectos secundarios.

No beba jugo de toronja ni coma productos a base de toronja mientras toma IBRANCE, ya que pueden aumentar la cantidad de IBRANCE en la sangre.

Informe a su médico si comienza a tomar un nuevo medicamento. Tome IBRANCE exactamente como se lo indique su médico.

Si toma una dosis demasiado alta de IBRANCE, llame de inmediato a su médico o acuda a urgencias del hospital más cercano.

Le recomendamos que informe los eventos adversos relacionados con los productos de Pfizer llamando al 1-800-438-1985 (EE. UU. únicamente). Si lo prefiere, puede comunicarse directamente con la Administración de Medicamentos y Alimentos de los EE. UU. (Food and Drug Administration, FDA). Visite www.fda.gov/medwatch o llame al 1-800-FDA-1088. (EE. UU. únicamente).

INDICACIONES

IBRANCE cápsulas y comprimidos de 125 mg son un medicamento de venta con receta que se utiliza en adultos para el tratamiento del cáncer de mama con receptor hormonal positivo (HR+) y receptor 2 del factor de crecimiento epidérmico humano negativo (HER2-) que se ha propagado a otras partes del cuerpo (metastásico) en combinación con:

  • un inhibidor de la aromatasa como primera terapia hormonal en mujeres posmenopáusicas o en hombres, o bien,
  • fulvestrant en personas con progresión de la enfermedad después de la terapia hormonal.

Consulte la Información Completa de Prescripción y la Información Para el Paciente.

Consulte la Información Completa de Prescripción y la Información Para el Paciente.